• Special Issue Topic

    Integrated Approaches for Non-Small-Cell Lung Cancer

    Submission Deadline: December 31, 2023

    Guest Editors

    Dr. Alessandro Morabito E-Mail

    Director of Thoracic Medical Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy

    Research Keywords: Lung cancer; target based agents; angiogenesis inhibitors; immunotherapy; clinical trials

    Dr. Edoardo Mercadante E-Mail

    Director of Thoracic Surgery Unit, National Cancer Institute IRCCS ”Pascale Foundation”, Naples, Italy

    About the Special Issue

    The treatment landscape of patients with non-­small-­cell lung cancer (NSCLC) has dramatically changed in recent years, thanks to the improvement in the knowledge of the biology of NSCLC, the discovery of targetable oncogenic drivers, the positive results obtained with immunotherapy in different settings (advanced, locally advanced, adjuvant, neoadjuvant) and the optimal integration of surgery, radiotherapy and systemic treatments. Furthermore, thanks to the advent of technology, surgical minimally invasive treatments (Robotic and Thoracoscopic) are always less traumatic, thus, increasing the number of surgical candidates, even in fragile and with co-morbidities patients.

    For NSCLC patients with early and locally advanced disease a through therapeutic revolution is currently ongoing and a multidisciplinary approach is mandatory. This Special Issue will highlight the current state of treatment of early and locally advanced NSCLC patients, focusing on the approved indications of surgery, radiotherapy and systemic treatments, including chemotherapy, immunotherapy and targeted based agents. Moreover, the strategies to improve the results obtained to date and the challenge to face resistance disease will be discussed. Finally, the role of liquid biopsy in this setting and its potential implementation will be evaluated.

    The possible topics could be (but not limited to) :

    • The role of radioterapy in early stage NSCLC

    • Advancement in radiotherapy for locally advanced NSCLC

    • New surgical approaches for early stage NSCLC

    • Role of surgery for locally advanced NSCLC

    • Immunotherapy for locally advanced NSCLC

    • Target based agents for oncogene addicted locally advanced NSCLC

    • The role of liquid biopsy in early stage NSCLC

    • Advancement in the treatment of locally advanced NSCLC

    • Minimally invasive surgery and its efficacy on lymphadenectomy

    • Activity of a Lung Cancer MDT: benefits and barriers

    Keywords: Early stage NSCLC; locally advanced NSCLC; thoracic radiotherapy; thoracic surgery; adjuvant treatment; liquid biopsy; immunotherapy

    Call for Papers

    Published Articles

    Open Access
    Current status of molecular diagnostics for lung cancer
    The management of lung cancer (LC) requires the analysis of a diverse spectrum of molecular targets, including kinase activating mutations in EGFR, ERBB2 (HER2), BRAF and MET oncogenes, [...] Read more.
    Evgeny N. Imyanitov ... Sergey V. Orlov
    Published: June 27, 2024 Explor Target Antitumor Ther. 2024;5:742–765
    DOI: https://doi.org/10.37349/etat.2024.00244
    Times Cited: 0
    Open Access
    Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach
    Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advan [...] Read more.
    Francesca Di Pressa ... Alessio Bruni
    Published: May 17, 2024 Explor Target Antitumor Ther. 2024;5:449–464
    DOI: https://doi.org/10.37349/etat.2024.00228
    Times Cited: 0
    Open Access
    Improving the quality of patient care in lung cancer: key factors for successful multidisciplinary team working
    International Guidelines as well as Cancer Associations recommend a multidisciplinary approach to lung cancer care. A multidisciplinary team (MDT) can significantly improve treatment decision-making [...] Read more.
    Alessandro Morabito ... Giacomo Pascarella
    Published: March 21, 2024 Explor Target Antitumor Ther. 2024;5:260–277
    DOI: https://doi.org/10.37349/etat.2024.00217
    Open Access
    Mini Review
    Management of stage III non-small-cell lung cancer: rays of hope
    Lung cancer remains the most common cause of cancer death across the world. Non-small-cell lung cancer (NSCLC) represents the most frequent type of lung cancer and is frequently diagnosed at an adva [...] Read more.
    Floryane Kim ... Alex Friedlaender
    Published: February 19, 2024 Explor Target Antitumor Ther. 2024;5:85–95
    DOI: https://doi.org/10.37349/etat.2024.00206
    Times Cited: 0
    Open Access
    Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
    Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) is now a drugable oncogenic driver and the KRAS G12C variant responds clinically to sotorasib and adagrasib that covalently block the cystein [...] Read more.
    Gerhard Hamilton ... Barbara Rath
    Published: October 26, 2023 Explor Target Antitumor Ther. 2023;4:1027–1038
    DOI: https://doi.org/10.37349/etat.2023.00178
    Open Access
    Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
    Despite consistent progress in prompt diagnosis and curative therapies in the last decade, lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties compared to pros [...] Read more.
    Parth Malik ... Tapan Kumar Mukherjee
    Published: October 10, 2023 Explor Target Antitumor Ther. 2023;4:850–895
    DOI: https://doi.org/10.37349/etat.2023.00171